Long Focus Capital shows 0% Adaptimmune (ADAPY) ADS ownership in 13G

Rhea-AI Filing Summary

Adaptimmune Therapeutics plc received a Schedule 13G from Long Focus Capital Management, LLC and John Helmers regarding its American Depositary Shares, each representing 6 ordinary shares. As of the close of business on December 31, 2025, the filing reports beneficial ownership of 0 ADS, representing 0% of the class, with no sole or shared voting or dispositive power.

The securities referenced were purchased in client accounts managed by Long Focus, and no individual client owns more than 5% of the class. The filers certify the holdings are in the ordinary course of business and not for influencing control of Adaptimmune.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ADAPTIMMUNE THERAPEUTICS PLC

(Name of Issuer)

American Depositary Shares, each representing 6 Ordinary Shares

(Title of Class of Securities)

00653A107

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00653A107

1

Names of Reporting Persons

LONG FOCUS CAPITAL MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 00653A107

1

Names of Reporting Persons

JOHN HELMERS

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ADAPTIMMUNE THERAPEUTICS PLC
(b)	Address of issuer's principal executive offices: 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire OX14 4RX United Kingdom
Item 2.
(a)	Name of person filing: LONG FOCUS CAPITAL MANAGEMENT LLC JOHN HELMERS
(b)	Address or principal business office or, if none, residence: 207 CALLE DEL PARQUE A&M TOWER, 8TH FLOOR SAN JUAN, PR 00912
(c)	Citizenship: Long Focus Capital Management, LLC, a Delaware single member limited liability company; and John Helmers, a United States citizen.
(d)	Title of class of securities: American Depositary Shares, each representing 6 Ordinary Shares
(e)	CUSIP No.: 00653A107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row (9) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2025. Long Focus Capital Management, LLC and John Helmers directly own no American Depositary Shares. Pursuant to investment management agreements with its clients, Long Focus Capital Management, LLC maintains dispositive and voting power with respect to the securities held in its clients' accounts. John Helmers controls Long Focus Capital Management, LLC.
(b)	Percent of class: The information required by Item 4(b) is set forth in Row (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row (5) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2025.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row (6) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2025.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row (7) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2025.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row (8) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2025.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Securities reported on this statement on Schedule 13G as being beneficially owned by Long Focus Capital Management, LLC were purchased on behalf of its clients and no one client owns more than 5 percent of a class of such securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

LONG FOCUS CAPITAL MANAGEMENT, LLC

Signature:	/s/ John Helmers
Name/Title:	Managing Member
Date:	02/17/2026

JOHN HELMERS

Signature:	/s/ John Helmers
Name/Title:	John Helmers
Date:	02/17/2026

FAQ

What does the Schedule 13G for ADAPY report about Long Focus Capital Management's stake?

The Schedule 13G reports that Long Focus Capital Management and John Helmers beneficially own 0 American Depositary Shares of Adaptimmune, representing 0% of the class as of December 31, 2025, with no sole or shared voting or dispositive power.

Which security of Adaptimmune Therapeutics plc (ADAPY) is covered in this Schedule 13G filing?

The filing covers Adaptimmune’s American Depositary Shares, with each ADS representing 6 ordinary shares. The report focuses on beneficial ownership levels of these ADSs as of December 31, 2025 by Long Focus Capital Management and John Helmers.

How much of Adaptimmune’s ADS class does Long Focus Capital Management report owning?

Long Focus Capital Management reports beneficial ownership of 0 ADS, corresponding to 0% of the outstanding class. The filing also shows no sole or shared voting or dispositive power over Adaptimmune ADSs as of December 31, 2025.

Who are the reporting persons in the Adaptimmune (ADAPY) Schedule 13G filing?

The reporting persons are Long Focus Capital Management, LLC, a Delaware limited liability company, and John Helmers, a United States citizen who controls Long Focus. Both are identified as having 0% beneficial ownership of Adaptimmune’s ADSs.

What does the filing say about Long Focus clients’ holdings of Adaptimmune ADSs?

The filing notes that securities reported were purchased on behalf of clients of Long Focus Capital Management. It specifies that no single client owns more than 5% of the class of Adaptimmune American Depositary Shares referenced in the report.

Does the Schedule 13G indicate an attempt to influence control of Adaptimmune Therapeutics (ADAPY)?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Adaptimmune, nor in connection with any transaction intended to have that control-related effect.